An interventional study of Axana Scan and MRI in Stroke, Acute Stroke and Ischemic Stroke, sponsored by Wellumio R&D Australia Pty Ltd. Completed at 1 site in Australia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-07.
Sponsored by Wellumio R&D Australia Pty Ltd · Not applicable, Interventional, and Diagnostic
Among 121 studies in Stroke with a site in Australia — 21 open to participants now, 28 under way, 10 of them phase 3. Stroke · Australia.
Among the 121 studies in Stroke with a site in Australia, this one is the 89th largest by enrollment of the 107 interventional ones that give a count, is one of 8 that started in 2024, is one of 28 with no phase, and was the 110th registered.
8,255 studies on the registry are indexed under Stroke; 2,056 are open to participants now.
Browse Stroke studies →21 of the 121 studies in Stroke with a site in Australia are open now. Recruiting first, the newest first:
University of Calgary · Sites in Australia, Canada
Ages 18+
Eli Lilly and Company · Sites in Australia, Argentina, Austria and 35 more countries
Ages 50+
The Florey Institute of Neuroscience and Mental Health · Sites in Australia
Ages 18–55
Transverse Medical, Inc. · Sites in Australia
Ages 18+
EMVision Medical Devices Ltd · Sites in Australia, United States
Ages 22+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 1,415 Stroke studies recruiting now, 697 (49%) set no upper age limit and 280 (20%) stop at 75 or younger; 77 take children under 18; 196 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
121 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 19 · Phase 3 50 · Phase 4 10
First in 1996; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is above the median of 49 across 6,024 interventional studies indexed under Stroke.
Median enrollment 585 across the 107 interventional studies, 626 across the 13 observational. Of the 87 that completed or were terminated, 34 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 121 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Wellumio R&D Australia Pty Ltd as lead sponsor.
Wellumio R&D Australia Pty Ltd has 1 study filed under Stroke — fewer than ten, so there is no comparison to draw.
5 of the studies in Stroke with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06527261University of MelbourneElectronic Capturing of Activities During REhabilitation for Upper Limb After Stroke | 2026-12 |
| NCT06495671University of MelbourneAustralasian Nanoparticle-mediated Magnetically Enhanced Diffusion for Ischemic Stroke | 2026-12-31 |
| NCT07019493The Florey Institute of Neuroscience and Mental HealthYoung Stroke Service Deep Phenotyping: Exploring Recovery in Young Adult Survivors of Stroke | 2026-12-31 |
| NCT06429332Region SkaneInternational Care Bundle Evaluation in Cerebral Hemorrhage Research | 2027-03-01 |
| NCT06226805Basking Biosciences, Inc.Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) | 2027-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 121 studies in Stroke with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the safety and feasibility of the Wellumio 'Axana' device in the hospital setting with healthy controls and patients.
This study aims to identify if the Wellumio 'Axana' device, a portable 0.1T MRI, is feasible, safe and reliable for use in the hospital setting.
Primary Objective
- To assess the safety (adverse events) and feasibility (ability to acquire a scan, in a timely manner without technical fault) of the Wellumio 'Axana' device in the hospital setting with healthy controls and patients.
Secondary Objective
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy Participants:
Hospital Patients:
Exclusion Criteria:
General:
Healthy Participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy controls with no brain structural changes will be scanned up to 3 times in one session with the 'Axana' device, and have a concurrent hospital brain MRI scan.The hospital MRI performed should consist of a minimum of a T2, FLAIR, ADC, DWI and GRE.
Diagnostic Test: Axana Scan and MRI
Patients admitted to hospital with a stroke will be scanned with the 'Axana' device during their hospital stay. Patients will be booked in for a hospital MRI scan as per standard in-hospital processes. On the day of the MRI scan, patients will have two 'Axana' device scans (Scan 1\& 2). These scans must all happen on the same day and no strict order or scans are required. There must be no more than 6 hours between the hospital MRI and 'Axana' scans. The hospital MRI performed should consist of a minimum of a T2, FLAIR, ADC, DWI and GRE.
Diagnostic Test: Axana Scan and MRI
Patients will be booked in for a hospital MRI scan as per standard in-hospital processes. On the day of the MRI scan, patients will have two 'Axana' device scans (Scan 1 \& 2). These scans must all happen on the same day and no strict order or scans are required. There must be no more than 6 hours between the hospital MRI and 'Axana' scans. The hospital MRI performed should consist of a minimum of a T2, FLAIR, ADC, DWI and GRE.
Also known as: Axana Scan, MRI scan
Number of Participants With Device-Related Adverse Events
Number of participants experiencing one or more adverse events considered related to the Axana device or scanning procedure
Time frame: During the Axana scan and immediately following completion of the scan
Proportion of Axana Scan Attempts Successfully Completed Without Technical Failure
Proportion of attempted Axana scans successfully completed without a technical fault preventing scan acquisition
Time frame: During each Axana scanning session
Time Required to Complete an Axana Scan
Elapsed time, measured in minutes, required to complete an Axana scan
Time frame: During each Axana scanning session
User-Reported Usability of the Axana Device
Usability of the Axana device assessed using a post-scan questionnaire completed by the physician or device user. Questionnaire responses were collected throughout enrolment to evaluate user experience and changes associated with increasing familiarity with the device.
Time frame: Immediately after each Axana scanning session
Agreement Between Axana and Hospital MRI Findings
Agreement between findings obtained using the Axana device and findings from the hospital MRI examination performed on the same day
Time frame: Axana and hospital MRI examinations performed on the same day, with no more than 6 hours between examinations
Within-Participant Repeatability of Axana Scans
Repeatability of Axana scan findings assessed by comparing repeated Axana scans acquired from the same participant during the same scanning session
Time frame: Day 1 During the same Axana scanning session
Plan to share: No — The study is a first in man study serving as the basis of RD development and future trials
No publications or documents are linked to this record.
Ran from Jul 2024 to primary completion in Sep 2025, 14 months.
Of 144 industry-sponsored interventional studies with no phase under Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's 14 months is below that.
Counting every sponsor, half of 3,252 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.